Posts found in:
Grantees

A Diet and Activity Intervention to Improve Survival and Quality of Life in Obese Adolescents Receiving Therapy for Acute Lymphoblastic Leukemia Acute lymphoblastic leukemia is the most common childhood cancer and relapse is the leading cause of death. Obesity during treatment is associated with relapse and greater side effects. We propose to conduct a clinical […]

Identification and correction of T cell defects in patients with chronic lymphocytic leukemia and impact on T cell therapy. Patients with chronic lymphocytic leukemia can be treated with a variety of regimens, but only cell therapies such as transplant or genetically-modified T cells (CART19) can be curative. Our research proposes to test the combination of […]

Inhibition of Runx1 Tyrosine Phosphorylation in the Treatment of Human Leukemia Normal gene expression is controlled by proteins, called transcription factors, which bind to DNA and turn on or off nearby genes. Mutations in transcription factors occur frequently in cancer, leading to disordered gene expression. The transcription factor Runx1 is one of the most common […]

Role of regulated nutrient transporter expression in suppressing leukemia and lymphoma development. Because cancer cells grow very rapidly, they are very dependent on a high rate of nutrient flux into the cell. The Edinger Lab hopes to identify the molecular tricks that leukemia cells use to import nutrients more efficiently than normal cells. By understanding […]

Dr. Knoechel researches the enhancer rewiring in drug resistant T-ALL and its therapeutic implications. T-cell acute lymphoblastic leukemia (T-ALL) is a disease that affects children and young adults, for which outcome has remained poor, often due to rapid development of resistance to existing therapies. We propose to determine the epigenetic alterations responsible for drug resistance […]

Dr. Kentsis researches the blockade of autocrine signaling for curative therapy of acute myeloid leukemia. Acute myeloid leukemia (AML) is a blood cancer that frequently affects both children and adults. Current treatment of AML with chemotherapy is toxic, and new therapies are direly needed for patients whose disease is resistant to intensive chemotherapy. Our research […]

Dr. Tasian is researching FLT3 Receptor-Redirected Chimeric Antigen Receptor T Call Immunotherapy for High Risk Pediatric Leukemias. Many children with high risk acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) are resistant to chemotherapy and will relapse. We are testing new “killer T cell” immunotherapies in specialized leukemia mouse models with the goal of […]

DR. Mukherjee has been dissecting the roles of Yes-1, MIIt3 and Ctnnd1 in leukemia stem cell quiescence. Hematopoietic stem cells are maintained in deep quiescence in the bone marrow. A fundamental feature of leukemias is the disruption of this quiescence, resulting in unchecked proliferation. Our laboratory has used a novel high-throughput screen to identify 3 […]